MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 562049 | Name: KCA-1490

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KCA-1490 is a dual PDE3/4 inhibitor.

Chemical Structure

KCA-1490
KCA-1490
CAS#909719-71-7

Theoretical Analysis

MedKoo Cat#: 562049

Name: KCA-1490

CAS#: 909719-71-7

Chemical Formula: C14H13F3N4O2

Exact Mass: 326.0991

Molecular Weight: 326.27

Elemental Analysis: C, 51.54; H, 4.02; F, 17.47; N, 17.17; O, 9.81

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
KCA-1490; KCA 1490; KCA1490;
IUPAC/Chemical Name
6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one
InChi Key
IDPCPRHAKGSESY-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H13F3N4O2/c1-7-5-11(22)18-19-13(7)8-3-4-12(23-2)21-9(8)6-10(20-21)14(15,16)17/h3-4,6-7H,5H2,1-2H3,(H,18,22)
SMILES Code
O=C1CC(C)C(C2=CC=C(OC)N3C2=CC(C(F)(F)F)=N3)=NN1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 326.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kojima A, Takita S, Sumiya T, Ochiai K, Iwase K, Kishi T, Ohinata A, Yageta Y, Yasue T, Kohno Y. Phosphodiesterase inhibitors. Part 6: design, synthesis, and structure-activity relationships of PDE4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory activity. Bioorg Med Chem Lett. 2013 Oct 1;23(19):5311-6. doi: 10.1016/j.bmcl.2013.07.069. Epub 2013 Aug 8. PubMed PMID: 23988356. 2: Ochiai K, Takita S, Kojima A, Eiraku T, Iwase K, Kishi T, Ohinata A, Yageta Y, Yasue T, Adams DR, Kohno Y. Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. Bioorg Med Chem Lett. 2013 Jan 1;23(1):375-81. doi: 10.1016/j.bmcl.2012.08.121. Epub 2012 Nov 9. PubMed PMID: 23200255. 3: Ochiai K, Takita S, Kojima A, Eiraku T, Ando N, Iwase K, Kishi T, Ohinata A, Yageta Y, Yasue T, Adams DR, Kohno Y. Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5833-8. doi: 10.1016/j.bmcl.2012.07.088. Epub 2012 Jul 31. PubMed PMID: 22884989. 4: Ochiai K, Takita S, Eiraku T, Kojima A, Iwase K, Kishi T, Fukuchi K, Yasue T, Adams DR, Allcock RW, Jiang Z, Kohno Y. Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity. Bioorg Med Chem. 2012 Mar 1;20(5):1644-58. doi: 10.1016/j.bmc.2012.01.033. Epub 2012 Jan 28. PubMed PMID: 22336247. 5: Ochiai K, Ando N, Iwase K, Kishi T, Fukuchi K, Ohinata A, Zushi H, Yasue T, Adams DR, Kohno Y. Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5451-6. doi: 10.1016/j.bmcl.2011.06.118. Epub 2011 Jul 2. PubMed PMID: 21764304.

View History

Windorphen

Windorphen

Featured